Location:
W320 Chapin, Orange County Convention Center, West Building
Session Description
This session explores the processes and opportunities to innovate in the development of new therapeutic agents for AKI. Particular emphasis is given to emerging concepts on clinical trial design, end point selection, and targeting the transition from AKI to CKD.
Learning Objective(s)
• Identify how AKI models, model organisms, and experimental outcomes map to discrete AKI syndromes and trial populations
• Describe how innovative end point selection in early-phase clinical trials could bolster the pipeline for AKI therapeutics
• Discuss emerging trial design concepts and how they might be applied to AKI
Learning Pathway(s)
• AKI and Critical Care
• Pharmacology
Moderators
• Javier A. Neyra, MD, MS, FASN
• Danielle Soranno, MD
Presentations
• What Makes for an Exciting Preclinical Data Packet for AKI or CKD?
10:30 AM EDT – 11:00 AM EDT
Katalin Susztak, MD, PhD
• Rethinking End Points in Early Phase AKI Studies
11:00 AM EDT – 11:30 AM EDT
Sushrut S. Waikar, MD, MPH
• An Adaptive Trial Platform for AKI? Promises and Perils
11:30 AM EDT – 12:00 PM EDT
Kathleen D. Liu, MD, PhD, FASN
• Lessons for AKI Research from Pragmatic Trials
12:00 PM EDT – 12:30 PM EDT
Miguel A. Vazquez, MD, FASN